← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Nitrosoureas
streptozocin
L01AD04
Forms & Strengths
- Powder for injection: 1 g per vial
Adult Dosing
- Metastatic islet cell carcinoma of the pancreas: 500 mg/m² intravenously daily for 5 consecutive days every 6 weeks
- Alternative schedule: 1000 mg/m² IV weekly for 2 doses, then increased to max 1500 mg/m² weekly if no progression/toxicity
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of metastatic islet cell carcinoma of the pancreas
Mechanism of Action
- Alkylating agent of the nitrosourea class that cross-links DNA strands, inhibiting DNA replication and transcription
- Exhibits a high selective toxicity for the insulin-producing beta cells of the pancreas
Contraindications
- Hypersensitivity to streptozocin or any component of the formulation
- Severe baseline renal impairment due to high nephrotoxicity
Adverse Reactions
- Severe nephrotoxicity (proteinuria, azotemia, renal tubular acidosis)
- Severe nausea and vomiting (nearly 100% incidence without prophylaxis)
- Myelosuppression (leukopenia, thrombocytopenia)
- Mild to moderate hepatotoxicity (elevated transaminases, alkaline phosphatase)
- Diarrhea, anorexia, and localized pain at the injection site
Drug Interactions
- Other nephrotoxic agents (e.g., aminoglycosides, amphotericin B, cisplatin) increase the risk of severe renal impairment
- Bone marrow depressants (e.g., radiation, other antineoplastic agents) exacerbate myelosuppression
- Phenytoin: streptozocin may decrease seizure threshold or alter phenytoin levels
Curated Content: Needs Vetting Before Put to Clinical Use